Pharma Major, Lupin Limited announced that its U.S subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has been granted final approval for the company’s generic versions of Merck’s antihypertensive agents *Hyzaar® (hydrochlorothiazide; losartan potassium) and *Cozaar® (losartan potassium) by the U.S. Food and Drug Administration.
The brand products had combined annual sales of approximately $1.6 billion in the United States, based on IMS sales data for the 12 months ended June 2010.
